Benzinga | Dec 9, 2021 09:47PM EST

Wells Fargo Initiates Coverage On Vertex Pharmaceuticals with Overweight Rating, Announces Price Target of $270

Wells Fargo analyst Mohit Bansal initiates coverage on Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight rating and announces Price Target of $270.